FDA Approval Alert: The Need-to-Know | Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced or Metastatic Urothelial Carcinoma

Oncology pharmacists are important to the oncology care team, as they can bring a unique perspective to treatment planning, according to Kirollos S. Hanna, PharmD, BCPS, BCOP, FACC.

Neuropathy is an adverse effect that can occur when enfortumab veodtin is administered to patients with locally advanced or metastatic urothelial carcinoma.

Patients with locally advanced or metastatic urothelial cancer may now receive enfortumab vedotin plus pembrolizumab following its approval by the FDA.